AmerisourceBergen Co. (NYSE:ABC) CEO Steven H. Collis sold 12,784 shares of AmerisourceBergen stock in a transaction that occurred on Tuesday, April 20th. The shares were sold at an average price of $120.07, for a total transaction of $1,534,974.88. Following the completion of the sale, the chief executive officer now owns 206,347 shares of the company’s stock, valued at $24,776,084.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of ABC stock opened at $120.89 on Friday. AmerisourceBergen Co. has a twelve month low of $81.51 and a twelve month high of $121.66. The stock’s fifty day simple moving average is $115.06 and its 200 day simple moving average is $105.57. The company has a quick ratio of 0.60, a current ratio of 0.98 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $24.75 billion, a P/E ratio of -7.20, a P/E/G ratio of 1.13 and a beta of 0.57.
AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings results on Wednesday, February 3rd. The company reported $2.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.94 by $0.24. The firm had revenue of $52.50 billion for the quarter, compared to analyst estimates of $50.49 billion. AmerisourceBergen had a positive return on equity of 65.93% and a negative net margin of 1.80%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $1.76 earnings per share. As a group, equities research analysts expect that AmerisourceBergen Co. will post 8.38 EPS for the current fiscal year.
ABC has been the subject of several analyst reports. Mizuho lifted their price objective on AmerisourceBergen from $104.00 to $114.00 and gave the company a “neutral” rating in a report on Tuesday, February 9th. They noted that the move was a valuation call. Argus increased their price objective on shares of AmerisourceBergen from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, January 21st. They noted that the move was a valuation call. Deutsche Bank Aktiengesellschaft boosted their target price on shares of AmerisourceBergen from $111.00 to $115.00 and gave the company a “hold” rating in a research report on Thursday, January 7th. Evercore ISI upgraded shares of AmerisourceBergen from an “in-line” rating to an “outperform” rating in a research report on Thursday, February 4th. Finally, Morgan Stanley boosted their price objective on shares of AmerisourceBergen from $130.00 to $138.00 and gave the company an “overweight” rating in a research report on Monday, February 8th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. AmerisourceBergen currently has an average rating of “Buy” and a consensus target price of $121.67.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Read More: Why do earnings reports matter?
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.